Takeda Ventures

About The Fund

Takeda Ventures, Inc. is the corporate venture capital arm of Takeda, headquartered in Palo Alto, California. Established in 2001, the firm is dedicated to advancing disruptive technologies and therapeutic solutions for patients by making venture-based investments. They predominantly invest in early-stage, preclinical opportunities, and products that align with and complement Takeda’s R&D pipeline, focusing on generating strategic growth opportunities for Takeda through building, managing, and investing in innovative companies. Takeda Ventures sets out to support therapeutic innovation by offering access to the resources of a multinational pharmaceutical company. They have a strong commitment to fostering a portfolio of companies in areas aligned with Takeda's R&D pillars, which include Oncology, Rare Genetics & Hematology, Neuroscience, and Gastrointestinal and Inflammation. Operating as strategic investors, Takeda Ventures is open to partnering with academic innovators, entrepreneurs, and venture investors. Their investment range typically falls between $1,000,000 and $5,000,000, with a sweet spot at around $2,500,000, and they engage in Seed, Series A, and Series B funding rounds. The fund's type is defined as Corporate VC and operates with the philosophy to accelerate the development of breakthrough science by combining Takeda’s expertise and capabilities with the innovation of their partners. Takeda Ventures looks to foster relationships that provide mutual benefits and propel R&D strategy forward, through various forms of collaboration including research partnerships, in-licensing, out-licensing, co-development, commercialization, NewCo creation, and acquisitions.